Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.

Abstract:

:Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs55829688 (T > C) was significantly associated with prognosis of AML (p = 0.018). Patients with rs55829688 CC genotype showed higher GAS5 expression in peripheral blood mononuclear cells (PBMCs) (p = 0.025) and harbored a longer platelets recovery (p = 0.040) than carriers of rs55829688T allele. In vitro study indicated that GAS5 promoter harboring the rs55829688C allele showed marginally increased reporter gene activity (p = 0.019), and the promoter activity was increased by TP63 in a dose-dependent manner (P = 0.001). Moreover, GAS5 higher expression predict shorter AML overall survival (OS), which validated in GEO GSE12417 dataset (p = 0.011). In conclusion, rs55829688 polymorphism could increase GAS5 expression by interacting with TP63, which might aggravate the myelosuppression and in turn lead to poor prognosis in AML. Trail registration number: ChiCTR-PPC-14005297.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

doi

10.1080/10428194.2016.1266626

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

1948-1957

issue

8

eissn

1042-8194

issn

1029-2403

journal_volume

58

pub_type

杂志文章
  • Case 30: hypereosinophilia.

    abstract::A young man presented with systemic symptoms and marked eosinophilia. Subsequently cyclical weight gain and edema contributed to a diagnosis. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600724878

    authors: Marks AJ,Abdalla SH,Cross NC,Bain BJ

    更新日期:2006-08-01 00:00:00

  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • Expression of the IL2 receptor alpha, beta and gamma chains in hairy cell leukemia.

    abstract::The expression of the interleukin 2 (IL2) receptor chains was investigated by immunofluorescence and mRNA analysis in typical and variant hairy cell leukemia (HCL) cases. While typical hairy cells express both the alpha and the beta chains, variant HCL express the IL2 receptor beta chain on the surface membrane but no...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:

    authors: de Totero D,Carbone A,Tazzari PL,Raspadori D,Ventura A,Reato G,Lauria F,Foa R

    更新日期:1994-01-01 00:00:00

  • Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia.

    abstract::We prospectively examined the frequency of the t(12;21)TEL-AML1 fusion in 504 children with newly diagnosed standard risk ALL using RT-PCR assays. Cells from 95 patients (18.8%) were TEL-AML1+. There was a significantly higher frequency of pseudodiploidy among the TEL-AML1+ cases (39.4% versus 14.1%, P = 0.001), prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097675

    authors: Uckun FM,Pallisgaard N,Hokland P,Navara C,Narla R,Gaynon PS,Sather H,Heerema N

    更新日期:2001-06-01 00:00:00

  • CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: a retrospective study.

    abstract::The risk for opportunistic infections is correlated with low CD4+ T lymphocyte counts in patients with HIV. We performed a retrospective analysis in 54 patients with multiple myeloma undergoing high-dose melphalan chemotherapy + autologous peripheral blood stem cell transplantation to better define the value of routin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601094347

    authors: Gorschlüter M,Glasmacher A,Sarazin S,Hackbarth F,Hoebert E,Orlopp K,Schmidt-Wolf IG,Mey U

    更新日期:2007-03-01 00:00:00

  • NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

    abstract::The t(5;17) variant of acute promeylocytic leukemia (APL) expresses a fusion of nucleophosmin (NPM) with the retinoic acid receptor alpha (RARA). We have previously shown that NPM-RAR is a binding partner of the tumor necrosis factor (TNF) receptor type-I-associated DEATH domain protein, TRADD. Binding of TNF to its r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1023799

    authors: Chattopadhyay A,Abecassis I,Redner RL

    更新日期:2015-01-01 00:00:00

  • Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.

    abstract::Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001697395

    authors: Lester R,Li C,Phillips P,Shenkier TN,Gascoyne RD,Galbraith PF,Vickars LM,Leitch HA

    更新日期:2004-09-01 00:00:00

  • Pulmonary embolism and thrombotic thrombocytopenic purpura in acute promyelocytic leukemia treated with all-trans retinoic acid.

    abstract::We describe a patient with acute promyelocytic leukemia (APL) who developed pulmonary embolism (PE) and thrombotic thrombocytopenic purpura (TTP) during remission induction all-trans retinoic acid (ATRA) therapy. A 44-year-old man was diagnosed with APL and was treated with ATRA. On day 14, he developed PE, and on day...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178790

    authors: Fujita H,Takemura S,Hyo R,Tanaka M,Koharazawa H,Fujisawa S,Kanamori H,Ishigatsubo Y

    更新日期:2003-09-01 00:00:00

  • Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.

    abstract::The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1466294

    authors: Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

    更新日期:2019-01-01 00:00:00

  • Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.

    abstract::We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701885545

    authors: Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

    更新日期:2008-04-01 00:00:00

  • Mimic of manganese superoxide dismutase induces apoptosis in human acute myeloid leukemia cells.

    abstract::Abstract Increasing manganese superoxide dismutase (MnSOD) expression can suppress the malignant phenotype in various cancer cell lines and suppress tumor formation in xenograft and transgenic mouse models. A mimic of manganese superoxide dismutase (MnSODm), synthesized by a chemical method, has been shown to possess ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.825904

    authors: Wang YH,Xu XJ,Zhang LF,Li HL

    更新日期:2014-05-01 00:00:00

  • Chemotherapy alone may be an efficient alternative in the treatment of early stage Hodgkin's disease if optimal radiotherapy is not available.

    abstract::Because radiotherapy (RT) equipment technology in some developing countries is outdated, its side effects are more frequent and severe and its efficacy suboptimal, whereas chemotherapy (CT) meeting international standards is generally more consistent. With this in mind, we treated 29 patients with stages I and II Hodg...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709068285

    authors: Ruiz-Argüelles GJ,Gómez-Almaguer D,Apreza-Molina MG

    更新日期:1997-09-01 00:00:00

  • Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

    abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701837330

    authors: Coleman M,Martin P,Ruan J,Furman R,Niesvizky R,Elstrom R,George P,Leonard J,Kaufmann T

    更新日期:2008-03-01 00:00:00

  • Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia.

    abstract::Hairy cell leukemia (HCL), a rare haematological disorder of B-cell origin, mainly presents with bone marrow infiltration, haematopoietic insufficiency, and splenomegaly. In some cases, osteolytic lesions can be observed. Many of these clinical features, especially haematopoietic insufficiency and osteolytic lesions a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509056850

    authors: Schmid M,Porzsolt F

    更新日期:1995-05-01 00:00:00

  • Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.

    abstract::The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000030054

    authors: Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

    更新日期:2003-02-01 00:00:00

  • Early cytoreduction: a major prognostic factor in adult acute lymphoblastic leukemia.

    abstract::Prognostic factors in acute lymphoblastic leukemia (ALL) are used for treatment stratification of ALL. Definition of simple parameters such as the presence or absence of peripheral leukemic cells after one week of treatment could help for stratification. A retrospective study was conducted on 79 previously untreated a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049746

    authors: Legrand O,Marie JP,Cadiou M,Blanc C,Ramon S,Zittoun R

    更新日期:1994-11-01 00:00:00

  • Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

    abstract::We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260126

    authors: Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

    更新日期:2017-08-01 00:00:00

  • Predicting long-term survival in multiple myeloma patients following autotransplants.

    abstract::Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000067567

    authors: Fassas AB,Van Rhee F,Tricot G

    更新日期:2003-05-01 00:00:00

  • Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences.

    abstract::In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709042502

    authors: Gisslinger H,Kurzrock R,Wetzler M,Tucker S,Kantarjian H,Robertson B,Talpaz M

    更新日期:1997-03-01 00:00:00

  • Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.

    abstract::Patients with higher-risk MDS have an abysmal survival record and should be started immediately on therapy, the most common of which being the hypomethylating agents, azacitidine or decitabine. Patients achieving a complete or partial response or hematologic improvement have been shown in two separate studies to have ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2015.1063149

    authors: Sekeres MA

    更新日期:2015-01-01 00:00:00

  • Daratumumab for the treatment of AL amyloidosis.

    abstract::Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1485914

    authors: Sidiqi MH,Gertz MA

    更新日期:2019-02-01 00:00:00

  • Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.

    abstract::The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.944521

    authors: Reinke EN,Bera S,Diamond AM

    更新日期:2015-04-01 00:00:00

  • Leukoencephalopathy in childhood acute lymphoblastic leukemia with t(1;19).

    abstract::To clarify the incidence of leukoencephalopathy in patients with t(1;19) and their clinical characteristics, we studied 239 acute lymphoblastic leukemia (ALL) cases. The 1;19 translocation was found in 20 (8.5%) of the 239 children with ALL. Leukoencephalopathy occurred in 2 (10%) patients with t(1;19) during the earl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909093734

    authors: Shikano T,Kobayashi R,Ishikawa Y

    更新日期:1999-03-01 00:00:00

  • Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.

    abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000016078

    authors: Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

    更新日期:2002-10-01 00:00:00

  • Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.

    abstract::Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290016944

    authors: Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

    更新日期:2002-04-01 00:00:00

  • Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    abstract::High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068053

    authors: Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

    更新日期:1991-01-01 00:00:00

  • Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

    abstract::Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309149119

    authors: Hagemeister FB

    更新日期:1993-01-01 00:00:00

  • Mechanisms of protection of hematopoietic stem cells from irradiation.

    abstract::Current therapies for the treatment of malignancies are associated with significant limitations to the hematopoietic system since chemotherapy and radiation therapy do not discriminate between normal and malignant cells. Since bone marrow depression occurs at low to midlethal doses of irradiation, approaches to improv...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409051648

    authors: Zucali JR

    更新日期:1994-03-01 00:00:00

  • DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

    abstract::This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1397659

    authors: Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

    更新日期:2018-08-01 00:00:00

  • Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.

    abstract::Post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) is a severe complication in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. Central nervous system (CNS) involvement of PTLD is a very rare event in patients with HSCT. As no established standard therapy i...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428194.2012.718342

    authors: Czyzewski K,Styczynski J,Krenska A,Debski R,Zajac-Spychala O,Wachowiak J,Wysocki M

    更新日期:2013-03-01 00:00:00